Back to Journals » Journal of Multidisciplinary Healthcare » Volume 14

Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence

Authors Magala Ssekandi A, Sserwanja Q, Olal E, Kawuki J, Bashir Adam M

Received 9 January 2021

Accepted for publication 3 March 2021

Published 16 March 2021 Volume 2021:14 Pages 659—663


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

Abdul Magala Ssekandi,1 Quraish Sserwanja,2 Emmanuel Olal,3 Joseph Kawuki,4 Mohammed Bashir Adam2

1Gift Life Care Clinic, Lira, Uganda; 2Programmes Department, GOAL Global, Khartoum, Sudan; 3Yotkom Medical Centre, Kitgum, Uganda; 4Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong

Correspondence: Abdul Magala Ssekandi
Gift Life Care Clinic Lira, Uganda
Tel +256784612652
Email [email protected]

Abstract: Pregnant women experience immune system changes to accommodate and tolerate the growing foetus, these changes also increase their susceptibility to viral infections such as SARS-COV-2. COVID-19 in pregnancy increases the likelihood of hospital admission and intensive care compared to non-pregnant women. Early administration of low-dose corticosteroids to patients with acute respiratory distress syndrome can reduce all-cause mortality among such patients. However, during pregnancy, prolonged use of corticosteroids that readily cross the placenta like dexamethasone can negatively impact both the mother and foetus. Evidence is thus needed on the choice, timing, and duration for corticosteroids use among pregnant women with COVID-19. This article aims to provide evidence on corticosteroid use in pregnant women with COVID-19. The RECOVERY trial deduced that low-dose dexamethasone (6 milligrams) reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen. Pregnant women in this trial received either oral prednisolone or intravenous hydrocortisone. Based on the RECOVERY trial findings, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends that pregnant women with moderate-to-severe COVID-19 receive oral prednisolone or intravenous hydrocortisone. However, currently, the World Health Organisation (WHO) does not explicitly specify which corticosteroid to use among pregnant women with moderate-to-severe COVID-19. We also note that there are no published articles on corticosteroid use among pregnant women with severe COVID-19 in Africa.

Keywords: COVID-19, corticosteroids, pregnant-women, prednisolone, preterm birth

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]